DURHAM, NC – The Clinical Trials Transformation Initiative (CTTI) has announced recommendations to streamline Good Clinical Practice (GCP) training of investigators who participate in clinical trials. GCP is an international standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials. According to CTTI’s executive director, Pamela Tenaerts, M.D., MBA, “Sponsors generally require clinical investigators to complete GCP training prior to participating in each clinical trial. This requirement can result in investigators who participate in multiple clinical trials receiving redundant GCP training numerous times within a single year.” “CTTI’s recommendations to eliminate redundant training and for sponsors to accept one another’s training would reduce unnecessary burden on sites and signify a major landmark for U.S.-based clinical research sites,” said Christine Pierre, president, Society for Clinical Research Sites (SCRS). “The Society for Clinical Research Sites is proud to have participated in this important initiative to maximize efficiency in GCP training.” The recommendations, presented in a public webinar hosted by SCRS, focus on four components of GCP training: minimum essential elements, training frequency, training format, and evidence of completion. Adaptability is encouraged as appropriate; for example, the frequency of training should be sufficiently flexible to accommodate different experience levels, gaps in training, etc., and should not be the same course every time. The recommendations were developed by a multi-stakeholder project team that considered the results of a literature review and analysis of some common GCP training programs, as well as discussions with experts on challenges regarding GCP training and possible solutions. The team expects to publish the complete details of the project in a peer-reviewed publication later this year. CTTI was established by Duke University and the FDA as a public-private partnership in 2007, and now comprises more than 60 member organizations working to identify and promote practices that will increase the quality and efficiency of clinical trials. More information about CTTI and its projects is available at www.ctti-clinicaltrials.org. SCRS was founded in 2012 in response to the growing need for a trade organization representative of the needs of clinical research sites globally. SCRS’s mission is to unify the voice of the global clinical research site community for greater site sustainability. Financial support for the work was provided by a grantfrom the FDA awarded to Duke University for CTTI, as well as pooled CTTI member funds and in-kind contributions.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.